Nautilus Biotechnology, Inc.
No enriched coverage for $NAUT in the last 7 days.
No SEC Form 4 filings for $NAUT in the last 30 days.
See all $NAUT insider activity →Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,
Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. naut-20260617 0001808805 FALSE 0001808805 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
AH Equity Partners Bio II, L.L.C. sold 384,026 indirectly-held shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($0.90M total) on 2026-06-02.
Recent NAUT coverage spans financial news, insider activity and earnings.
The 8-K provides fresh financial datapoints and a concrete roadmap realignment, which can reset near-term expectations for commercialization and cash burn.
Routine shareholder-meeting outcomes; no new operational or financial guidance, but it confirms governance decisions and auditor ratification.
Insider/10% owner selling can modestly pressure sentiment, but this Form 4 provides no new fundamental catalyst.
Insider selling by a 10% owner can pressure sentiment, but it is not a fundamental catalyst by itself without accompanying company news.
Nautilus Biotechnology reports improved quarterly financials with a net loss reduction and solid cash position, indicating ongoing progress towards commercialization.
alphai scores every news story that mentions NAUT with an AI model for sentiment and relevance, and aggregates insider trades from Nautilus Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,
6 min readNautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. naut-20260617 0001808805 FALSE 0001808805 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readAH Equity Partners Bio II, L.L.C. sold 384,026 indirectly-held shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($0.90M total) on 2026-06-02.
2 min readAH Equity Partners Bio II, L.L.C. sold 4,615,974 indirectly-held shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($10.85M total) on 2026-06-02.
2 min readNautilus Biotechnology (NASDAQ: NAUT) reported its Q1 2026 financial results, highlighting progress towards commercialization through its Iterative Mapping Early Access Program and the appointment of a new VP of Global Sales. The company posted a net loss of $14.7 million, an improvement from the previous year, and ended the quarter with $143.4 million in cash, cash equivalents, and investments. Nautilus is set to host a conference call on April 28, 2026, to discuss these results further.
2 min readNautilus Biotechnology Inc. (NAUT) is highlighted as a promising life sciences penny stock due to its innovative proteomics technology. Baylor College of Medicine is the first customer of Nautilus's Iterative Mapping Early Access Program, utilizing the technology to address fundamental problems in cancer biology through a National Institutes of Health U01 grant. Nautilus's platform provides end-to-end solutions for quantifying the proteome, including reagents, consumables, optical imaging systems, and affinity reagents.
3 min read• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a ...
2 min read• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a ...
2 min readImage source: The Motley Fool.Tuesday, Oct. 28, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min read• Allen Institute to employ Iterative Mapping, Nautilus' single-molecule proteomics method, to investigate connection between tau protein and Alzheimer's disease
3 min read
